SGLT2 is not expressed in pancreatic α- and β-cells, and its inhibition does not directly affect glucagon and insulin secretion in rodents and humans

• Main Authors: Heeyoung Chae (Author), Robert Augustin (Author), Eva Gatineau (Author), Eric Mayoux (Author), Mohammed Bensellam (Author), Nancy Antoine (Author), Firas Khattab (Author), Bao-Khanh Lai (Author), Davide Brusa (Author), Birgit Stierstorfer (Author), Holger Klein (Author), Bilal Singh (Author), Lucie Ruiz (Author), Michael Pieper (Author), Michael Mark (Author), Pedro L. Herrera (Author), Fiona M. Gribble (Author), Frank Reimann (Author), Anne Wojtusciszyn (Author), Christophe Broca (Author), Nano Rita (Author), Lorenzo Piemonti (Author), Patrick Gilon (Author)
• Format: Book
• Published: Elsevier, 2020-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objective: Sodium-glucose cotransporter 2 (SGLT2) inhibitors (SGLT2i), or gliflozins, are anti-diabetic drugs that lower glycemia by promoting glucosuria, but they also stimulate endogenous glucose and ketone body production. The likely causes of these metabolic responses are increased blood glucago...